MX2022013310A - Anticuerpos especificos para kras y sus usos. - Google Patents
Anticuerpos especificos para kras y sus usos.Info
- Publication number
- MX2022013310A MX2022013310A MX2022013310A MX2022013310A MX2022013310A MX 2022013310 A MX2022013310 A MX 2022013310A MX 2022013310 A MX2022013310 A MX 2022013310A MX 2022013310 A MX2022013310 A MX 2022013310A MX 2022013310 A MX2022013310 A MX 2022013310A
- Authority
- MX
- Mexico
- Prior art keywords
- kras
- specific antibodies
- kras specific
- gdp
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 3
- 229940124785 KRAS inhibitor Drugs 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
En la presente se proporcionan anticuerpos anti-KRas que se unen a KRas-GDP mutante y KRas-GDP mutante alquilado y métodos para su uso. En la presente también se proporcionan métodos para cribar inhibidores de KRas y métodos para medir la unión de KRas a los anticuerpos descritos en la presente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063018356P | 2020-04-30 | 2020-04-30 | |
PCT/US2021/029517 WO2021222333A1 (en) | 2020-04-30 | 2021-04-28 | Kras specific antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022013310A true MX2022013310A (es) | 2022-11-14 |
Family
ID=75977821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022013310A MX2022013310A (es) | 2020-04-30 | 2021-04-28 | Anticuerpos especificos para kras y sus usos. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220112308A1 (es) |
EP (1) | EP4143237A1 (es) |
JP (1) | JP2023524041A (es) |
KR (1) | KR20230002598A (es) |
CN (1) | CN115461375A (es) |
AU (1) | AU2021263767A1 (es) |
BR (1) | BR112022022021A2 (es) |
CA (1) | CA3174692A1 (es) |
CR (1) | CR20220598A (es) |
IL (1) | IL297672A (es) |
MX (1) | MX2022013310A (es) |
PE (1) | PE20231504A1 (es) |
TW (1) | TW202204420A (es) |
WO (1) | WO2021222333A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
US20240108618A1 (en) * | 2022-06-30 | 2024-04-04 | Eli Lilly And Company | Kras g12c inhibitor dosing regimens |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE337223B (es) | 1967-05-23 | 1971-08-02 | Pharmacia Ab | |
US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
GB1319315A (en) | 1969-06-19 | 1973-06-06 | Citizen Watch Co Ltd | Calendar timepiece |
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
BR0014480A (pt) | 1999-10-04 | 2002-06-11 | Medicago Inc | Método para regular a transcrição de genes estranhos |
KR101602870B1 (ko) * | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2018069871A2 (en) * | 2016-10-13 | 2018-04-19 | Sorrento Therapeutics, Inc. | Anti-kras binding proteins |
JP2021509020A (ja) * | 2017-11-16 | 2021-03-18 | オルム セラピューティクス インコーポレイテッドOrum Therapeutics Inc. | 細胞の細胞質に浸透して細胞内活性化されたrasを抑制する抗体及びその用途 |
-
2021
- 2021-04-28 IL IL297672A patent/IL297672A/en unknown
- 2021-04-28 AU AU2021263767A patent/AU2021263767A1/en active Pending
- 2021-04-28 KR KR1020227039081A patent/KR20230002598A/ko unknown
- 2021-04-28 CR CR20220598A patent/CR20220598A/es unknown
- 2021-04-28 CA CA3174692A patent/CA3174692A1/en active Pending
- 2021-04-28 PE PE2022002496A patent/PE20231504A1/es unknown
- 2021-04-28 BR BR112022022021A patent/BR112022022021A2/pt not_active Application Discontinuation
- 2021-04-28 US US17/243,129 patent/US20220112308A1/en active Pending
- 2021-04-28 MX MX2022013310A patent/MX2022013310A/es unknown
- 2021-04-28 TW TW110115400A patent/TW202204420A/zh unknown
- 2021-04-28 WO PCT/US2021/029517 patent/WO2021222333A1/en active Application Filing
- 2021-04-28 CN CN202180031399.8A patent/CN115461375A/zh active Pending
- 2021-04-28 JP JP2022566072A patent/JP2023524041A/ja active Pending
- 2021-04-28 EP EP21726496.9A patent/EP4143237A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115461375A (zh) | 2022-12-09 |
EP4143237A1 (en) | 2023-03-08 |
PE20231504A1 (es) | 2023-09-26 |
IL297672A (en) | 2022-12-01 |
CA3174692A1 (en) | 2021-11-04 |
AU2021263767A1 (en) | 2022-09-08 |
BR112022022021A2 (pt) | 2022-12-13 |
KR20230002598A (ko) | 2023-01-05 |
US20220112308A1 (en) | 2022-04-14 |
CR20220598A (es) | 2023-01-17 |
WO2021222333A1 (en) | 2021-11-04 |
JP2023524041A (ja) | 2023-06-08 |
TW202204420A (zh) | 2022-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022013310A (es) | Anticuerpos especificos para kras y sus usos. | |
MX2020012731A (es) | Inhibidores de kras g12c y metodos para su uso. | |
MX2020010836A (es) | Inhibidores de kras g12c y métodos para su uso. | |
MX2021005700A (es) | Inhibidores de kras g12c y metodos de uso de los mismos. | |
MX2020011582A (es) | Inhibidores de kras g12c y metodos para su uso. | |
MX2019000730A (es) | Proteinas multiespecificas de union al antigeno y metodos de uso de estas. | |
PH12021551171A1 (en) | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof | |
MX2022006578A (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos. | |
MX2023010430A (es) | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d). | |
MX2018008347A (es) | Metodos de tratamiento de canceres positivos para ace utilizando antagonistas de union a eje pd-1 y anticuerpos biespecificos anti-ace/anti-cd3. | |
MX2017013267A (es) | Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8). | |
AU2018338322A1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
MX2020010387A (es) | Metodos para detectar y cuantificar fgf21. | |
EA201190210A1 (ru) | Ингибиторы связывания киназы с белком | |
EP3924373A4 (en) | COMPOSITIONS AND METHODS FOR IDENTIFYING ANTIGEN-SPECIFIC T LYMPHOCYTES | |
CR20220646A (es) | Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos | |
MX2019004940A (es) | Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1. | |
MX2017009680A (es) | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). | |
JOP20210015A1 (ar) | تركيبات مضادات fcrn وطرق استخدامها | |
MX2021014973A (es) | Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso. | |
MX2023010499A (es) | Anticuerpos heterodimericos que se unen a cd3 y cldn6. | |
MX2023005081A (es) | Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos. | |
CR20220061A (es) | Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células | |
EP4028058A4 (en) | COMPOSITIONS AND METHODS FOR PRODUCING AND USING MULTISPECIFIC ANTIBODIES | |
EP3962926A4 (en) | COMPOSITIONS AND METHODS FOR MODULATION OF ANTIBODY ACTIVITY |